Bristol-Myers Squibb PE ratio BMY

Share price divided by earnings per share over the last twelve months, since 2011.

Today, Oct 23, 2026: 13.5×
10-year median: 19.9×
Against its 10-year history: 10th; percentile: 0 is its lowest day, 100 its highest
10-year range: 12.0× to 271×
Peer median: 41.4×

Bristol-Myers Squibb's PE ratio is 13.5× as of Oct 23, 2026: a share price of $61.48 against $4.54 of earnings per share over the last twelve months.

That is below its ten-year median of 19.9×, lower than on 90% of days in the last ten years.

Over that time it ranged from 12.0× in Jul 2019 to 271× in Oct 2018.

The median for 9 large drugmakers of a similar size is 41.4×.

PE ratio over time

median 19.9×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	13.5×	13.0×	20.9×
2025	18.5×	15.6×	19.5×
2024	12.7×	12.4×	14.0×
2023	13.0×	12.6×	24.3×
2022	23.4×	21.4×	28.0×
2021	n/m a value too high to mean anything
2020	72.4×	18.2×	79.1×
2019	18.6×	12.0×	58.7×
2018	57.9×	24.4×	271×
2017	24.1×	18.7×	30.0×
2016	29.2×	25.5×	81.7×
2015	64.9×	36.5×	65.2×
2014	36.6×	27.1×	37.6×
2013	31.8×	29.2×	60.6×
2012	29.3×	14.7×	30.8×
2011	18.3×	14.2×	18.3×

Against its peers

Companies in Drug Manufacturers - General nearest Bristol-Myers Squibb's size, closest first, today.

Company	PE ratio
BMYBristol-Myers Squibb	13.5×
PFEPfizer	39.5×
GILDGilead Sciences	n/m
AMGNAmgen	27.3×
MRKMerck	116×
BIIBBiogen	44.4×
ABBVAbbVie	80.7×
JNJJohnson & Johnson	40.0×
JAZZJazz Pharmaceuticals	14.6×
LLYEli Lilly and	42.7×
Peer median	41.4×

Where Bristol-Myers Squibb ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Bristol-Myers Squibb

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.